GNH USA

Europe — EMA

Obgemsa (Vibegron)

GNH USA supplies Obgemsa (Vibegron), a Beta-3 adrenergic receptor agonist for overactive bladder, urinary urgency and frequency. Request a quote for supply.

Vibegron

Request sourcing

1
Pack/s

What is Vibegron?

Vibegron, the active ingredient in Obgemsa, is a Beta-3 adrenergic receptor agonist presented as a oral tablet for oral use. It treats overactive bladder symptoms such as urinary urgency and frequency in adults.

GNH USA supplies Obgemsa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Vibegron used for?

Obgemsa belongs to the class of Beta-3 adrenergic receptor agonists and is indicated for conditions affecting bladder storage function. - Overactive bladder: reduces urgency episodes and increases bladder capacity. - Urinary urgency: diminishes the sudden need to void. - Urinary frequency: lowers the number of daily voids.

What are the side effects of Vibegron?

Common Side Effects: - Dry mouth: mild to moderate sensation of oral dryness. - Constipation: reduced bowel movement frequency. - Headache: transient cranial pain. - Hypertension: modest increase in blood pressure. - Nasopharyngitis: mild upper respiratory tract inflammation. - Urinary tract infection: bacterial infection of the urinary system.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: marked elevation of blood pressure requiring medical attention. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Angioedema: rapid swelling of face, lips, tongue, or throat. - Cardiac arrhythmia: irregular heart rhythm. - QT prolongation: potential for abnormal heart rhythm on ECG.

What precautions apply to Vibegron?

Before initiating therapy, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy if needed. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: observe blood pressure regularly. - Pregnancy: safety unknown; avoid unless benefits outweigh risks. - Concomitant β‑agonists: assess for additive cardiovascular effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

What does Vibegron interact with?

Vibegron may interact with several drug classes. Major Interactions (Avoid): - Other β3‑adrenergic agonists: risk of additive cardiovascular stimulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible enhanced blood‑pressure lowering. - Diuretics: monitor electrolytes and volume status. - Anticholinergic drugs: may influence bladder symptom control.

Frequently asked questions

What is Obgemsa used for?+
Obgemsa is prescribed to manage overactive bladder symptoms, including urinary urgency, frequency, and episodes of urge incontinence. It helps increase bladder capacity and reduce the sudden need to void, improving daily comfort and quality of life for adult patients.
How does Vibegron work?+
Vibegron selectively activates β3‑adrenergic receptors located on the detrusor smooth muscle of the bladder. This activation causes muscle relaxation, which expands functional bladder capacity and suppresses involuntary contractions that trigger urgency and frequent urination.
What is the usual dose of Obgemsa?+
The specific dose of Obgemsa is determined by the prescribing healthcare professional based on individual patient factors. The prescriber will select the appropriate strength and dosing schedule according to clinical guidelines and patient response.
Is Obgemsa safe during pregnancy or breastfeeding?+
Safety data for Vibegron in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.
How do I order Obgemsa from GNH USA?+
To request Obgemsa, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Obgemsa compare with the main alternative drug or class?+
The primary alternative class for overactive bladder is antimuscarinic agents such as oxybutynin. Compared with antimuscarinics, Vibegron (Obgemsa) has a different mechanism—β3‑adrenergic stimulation—and generally shows a lower incidence of dry mouth and constipation, though individual response may vary.
How should Obgemsa be stored and handled?+
Obgemsa should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.
How is Obgemsa administered?+
Obgemsa is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.
What are the most serious risks to watch for while taking Obgemsa?+
Serious risks include urinary retention, severe hypertension, allergic reactions such as rash or anaphylaxis, angioedema, and cardiac arrhythmias including QT prolongation. Patients should seek immediate medical attention if they experience difficulty urinating, a rapid rise in blood pressure, or signs of an allergic response.
Who should not use Obgemsa?+
Obgemsa is contraindicated in patients with known hypersensitivity to Vibegron or any of its excipients. Caution is advised for individuals with uncontrolled hypertension, severe hepatic impairment, or those taking other β3‑adrenergic agonists. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Vibegron
Route
Oral Use
Manufacturer
Pierre Fabre Medicament
Origin
EU

Related products

Obgemsa

Obgemsa

Vibegron

Pierre Fabre Medicament
EU
Obgemsa

Obgemsa

Vibegron

Pierre Fabre Medicament
EU
Obgemsa

Obgemsa

Vibegron

Pierre Fabre Medicament
EU